Bariatric Fundus Embolization Viable for Severely Obese Patients
By HospiMedica International staff writers Posted on 17 Apr 2019 |
Image: Dr. Aaron Fischman performing a bariatric embolization procedure (Photo courtesy of Mount Sinai Hospital).
Transarterial embolization of the gastric fundus in severely obese adults can suppress appetite and induce weight loss for up to 12 months, claims a new study.
Researchers at Johns Hopkins University (JHU; Baltimore, MD, USA), Mount Sinai Hospital (New York, NY, USA), and other institutions conducted a prospective study that recruited 20 severely obese adults (16 women; mean age 44 years) with a mean body mass index (BMI) of 45 kg/m2 to evaluate the safety and efficacy of bariatric embolization, an image-guided procedure that aims to induce metabolic changes by targeting the endocrine functions of the gastric fundus, which play a role in stimulating appetite.
Bariatric embolization was performed successfully in all participants, with no major adverse events. The mean excess weight loss was 8.2% at one month, 11.5% at three months, 12.8% at six months, and 11.5% at 12 months. Hunger or appetite decreased for four weeks after embolization, increasing again thereafter, but without reaching pre-embolization levels. Study participants also showed evidence of metabolic change, with decreases in hemoglobin A1c and total cholesterol (independent of weight loss), and concomitant increase in high-density lipoprotein (HDL) levels. The study was published on April 2, 2019, in Radiology.
“Weight loss of 5-10% has been found to reduce risks of cardiovascular disease and diabetes, including reduced hemoglobin A1c, increased HDL, reduced triglycerides, reduced blood pressure, and reduced need for diabetes and antihypertensive medications,” concluded lead author Clifford Weiss, MD, of JHU, and colleagues. “The changes in hemoglobin A1c, and the fact that they occurred independent of weight loss, may indicate that bariatric embolization alters the metabolic profile in ways similar to bariatric surgery, but to a lesser degree.”
Transarterial bariatric embolization of the gastric fundus delivers embolic microspheres into the gastric arteries to induce localized ischemia and modify appetite hormones, leading to weight reduction; early clinical trials have produced promising short-term results in animal models.
Related Links:
Johns Hopkins University
Mount Sinai Hospital
Researchers at Johns Hopkins University (JHU; Baltimore, MD, USA), Mount Sinai Hospital (New York, NY, USA), and other institutions conducted a prospective study that recruited 20 severely obese adults (16 women; mean age 44 years) with a mean body mass index (BMI) of 45 kg/m2 to evaluate the safety and efficacy of bariatric embolization, an image-guided procedure that aims to induce metabolic changes by targeting the endocrine functions of the gastric fundus, which play a role in stimulating appetite.
Bariatric embolization was performed successfully in all participants, with no major adverse events. The mean excess weight loss was 8.2% at one month, 11.5% at three months, 12.8% at six months, and 11.5% at 12 months. Hunger or appetite decreased for four weeks after embolization, increasing again thereafter, but without reaching pre-embolization levels. Study participants also showed evidence of metabolic change, with decreases in hemoglobin A1c and total cholesterol (independent of weight loss), and concomitant increase in high-density lipoprotein (HDL) levels. The study was published on April 2, 2019, in Radiology.
“Weight loss of 5-10% has been found to reduce risks of cardiovascular disease and diabetes, including reduced hemoglobin A1c, increased HDL, reduced triglycerides, reduced blood pressure, and reduced need for diabetes and antihypertensive medications,” concluded lead author Clifford Weiss, MD, of JHU, and colleagues. “The changes in hemoglobin A1c, and the fact that they occurred independent of weight loss, may indicate that bariatric embolization alters the metabolic profile in ways similar to bariatric surgery, but to a lesser degree.”
Transarterial bariatric embolization of the gastric fundus delivers embolic microspheres into the gastric arteries to induce localized ischemia and modify appetite hormones, leading to weight reduction; early clinical trials have produced promising short-term results in animal models.
Related Links:
Johns Hopkins University
Mount Sinai Hospital
Latest Critical Care News
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease
- Revascularization Improves Quality of Life for Patients with Chronic Limb Threatening Ischemia
- AI-Driven Prediction Models Accurately Predict Critical Care Patient Deterioration
- Preventive PCI for High-Risk Coronary Plaques Reduces Cardiac Events